Evidence map›Paper›PMID 39652777›Full record

ArticleBlood2025

The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas.

Nermin Kady, Suhaib Abdelrahman, Ahmar M Rauf, Alyssa Burgess, Jonathan Weiss, Hirushi Gunasekara, Neal Ramseier, Ira P Maine, Alejandro Zevallos-Morales, Vanessa Perez-Silos and 9 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Nermin KadyDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-8670-8752
Suhaib AbdelrahmanDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Ahmar M RaufDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-5639-2208
Alyssa BurgessDepartment of Chemistry, College of Liberal Arts and Sciences, University of Illinois Chicago, Chicago, IL.ORCID 0009-0000-8736-6125
Jonathan WeissDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Hirushi GunasekaraDepartment of Chemistry, College of Liberal Arts and Sciences, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-3750-2309
Neal RamseierDepartment of Chemistry, College of Liberal Arts and Sciences, University of Illinois Chicago, Chicago, IL.ORCID 0000-0001-8813-596X
Ira P MaineDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Alejandro Zevallos-MoralesDepartment of Pathology, University of Illinois Chicago, Chicago, IL.
Vanessa Perez-SilosDepartment of Pathology, University of Illinois Chicago, Chicago, IL.ORCID 0000-0001-9129-3221
Ashley WolfeDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-0340-2788
Alexandra C HristovDepartment of Pathology, University of Michigan, Ann Arbor, MI.
Noah A BrownDepartment of Pathology, University of Michigan, Ann Arbor, MI.
Kedar InamdarDepartment of Pathology, Henry Ford Hospital, Detroit, MI.
Maria SverdlovResearch Resources Center and Department of Pathology, University of Illinois Chicago, Chicago, IL.
Ying S HuDepartment of Chemistry, College of Liberal Arts and Sciences, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-3912-7063
Carlos Murga-ZamalloaDepartment of Pathology, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-2238-5066
Chenguang WangDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-9082-2117
Ryan A WilcoxDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-6420-0760

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Ultrasensitive quantification of cytokine release from T cellsR35GM146786 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ying Samuel Hu · 2022 to 2026
$2.2M
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomasR01CA236722 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILCOX, RYAN A · 2020 to 2024
$1.8M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA236722NIGMS NIH HHS R35 GM146786
6 · The paper itself

Abstract

abstractThe transcription factor GATA-binding protein 3 (GATA-3) and the transcriptional program it regulates have emerged as oncogenic drivers across diverse T-cell lymphomas (TCLs), many of which are resistant to conventional chemotherapeutic agents and characterized by recurrent losses of key tumor suppressor genes, including TP53 and PTEN, both of which are clients of the nuclear export protein XPO1. Here, we demonstrated that XPO1 is highly expressed by malignant T cells expressing GATA-3 and by lymphoma-associated macrophages (LAMs) within their tumor microenvironment (TME). Using complementary genetically engineered mouse models, we demonstrated that TP53- and/or phosphate and tensin homolog (PTEN)-deficient TCLs, and LAMs within their TME, are sensitive to the selective exportin-1 (XPO1) antagonist selinexor. In an effort to identify TP53- and PTEN-independent mechanisms, we used complementary and orthogonal approaches to investigate the role of eIF4E and XPO1-dependent messenger RNA nuclear export in these TCLs. We identified a novel role for eIF4E/XPO1 in exporting GATA-3 and GATA-3-dependent transcripts from the nucleus in TCLs, and in the export of therapeutically relevant transcripts, including colony-stimulating factor-1 receptor, from LAMs. Therefore, XPO1 antagonism, by impairing oncogenic transcriptional programs in TCLs and depleting LAMs from their TME, is a novel approach to target 2 independent dependencies in a group of therapeutically challenging TCLs.

Indexed as

Eukaryotic Initiation Factor-4EGATA3 Transcription FactorGene Expression Regulation, NeoplasticKaryopherinsLymphoma, T-CellReceptors, Cytoplasmic and NuclearTranscriptomeTumor MicroenvironmentAnimalsExportin 1 ProteinHumansHydrazinesMacrophagesMicePTEN PhosphohydrolaseTriazolesEukaryotic Initiation Factor-4EExportin 1 ProteinGata3 protein, mouseGATA3 Transcription FactorHydrazinesKaryopherinsPTEN PhosphohydrolaseReceptors, Cytoplasmic and NuclearselinexorTriazolesTumor Suppressor Protein p53

Identifiers

PMID39652777
PMCPMC11811937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.